TScan Therapeutics, Inc. (TCRX)
NASDAQ: TCRX · Real-Time Price · USD
2.170
-0.020 (-0.91%)
At close: Feb 21, 2025, 4:00 PM
2.180
+0.010 (0.46%)
After-hours: Feb 21, 2025, 7:47 PM EST
TScan Therapeutics Employees
TScan Therapeutics had 154 employees as of December 31, 2023. The number of employees increased by 16 or 11.59% compared to the previous year.
Employees
154
Change (1Y)
16
Growth (1Y)
11.59%
Revenue / Employee
$60,792
Profits / Employee
-$722,747
Market Cap
122.62M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 154 | 16 | 11.59% |
Dec 31, 2022 | 138 | 33 | 31.43% |
Dec 31, 2021 | 105 | 47 | 81.03% |
Dec 31, 2020 | 58 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
TCRX News
- 4 days ago - TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference - GlobeNewsWire
- 12 days ago - TScan Therapeutics: Finding Their Footing After An Eventful ASH Meeting - Seeking Alpha
- 2 months ago - TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium - GlobeNewsWire
- 2 months ago - TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank - GlobeNewsWire
- 2 months ago - TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition - GlobeNewsWire
- 2 months ago - TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years - GlobeNewsWire
- 2 months ago - TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Heme Development Strategy - GlobeNewsWire
- 3 months ago - TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition - GlobeNewsWire